AOD 9604

AOD 9604 is a research-grade synthetic peptide derived from the C-terminal fragment 176–191 of human growth hormone (hGH), engineered to study lipid metabolism and adipose tissue signaling without the full endocrine profile of hGH. It is primarily investigated as a lipolytic and anti-lipogenic fragment that may modulate fat oxidation and storage pathways in obesity and metabolic models.

Lipid Metabolism And Fat Loss Research

• Chronic administration in obese mouse models has been shown to reduce body weight gain, increase in vivo fat oxidation, and elevate plasma glycerol as an index of stimulated lipolysis, while not worsening insulin secretion or glycemia.​

• In vitro and in vivo work suggests AOD 9604 can enhance lipolytic activity and reduce lipogenesis in adipocytes, potentially via upregulation of beta‑3 adrenergic receptor expression and downstream signaling.

Mechanism Distinct From Full GH

• Does not appear to bind the hGH receptor or induce cell proliferation like intact growth hormone, supporting the concept that hGH can act as a pro-hormone whose fragments have unique, more selective actions.

• Early human safety and metabolism studies report favorable tolerability and rapid peptide degradation into shorter fragments that still retain partial anti-lipogenic activity, making it useful for mechanistic metabolic research.

For research purposes only. Not intended for human consumption, weight-loss therapy, or any medical use.